Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deferred Tax Liability (2016 - 2022)

Historic Non-Current Deferred Tax Liability for ImmunityBio (IBRX) over the last 7 years, with Q2 2022 value amounting to $162000.0.

  • ImmunityBio's Non-Current Deferred Tax Liability fell 470.59% to $162000.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $162000.0, marking a year-over-year decrease of 470.59%. This contributed to the annual value of $162000.0 for FY2021, which is 9665.15% down from last year.
  • As of Q2 2022, ImmunityBio's Non-Current Deferred Tax Liability stood at $162000.0, which was down 470.59% from $162000.0 recorded in Q1 2022.
  • Over the past 5 years, ImmunityBio's Non-Current Deferred Tax Liability peaked at $4.8 million during Q4 2020, and registered a low of $122000.0 during Q3 2018.
  • Over the past 4 years, ImmunityBio's median Non-Current Deferred Tax Liability value was $170000.0 (recorded in 2021), while the average stood at $658000.0.
  • Per our database at Business Quant, ImmunityBio's Non-Current Deferred Tax Liability plummeted by 9665.15% in 2021 and then plummeted by 470.59% in 2022.
  • Over the past 4 years, ImmunityBio's Non-Current Deferred Tax Liability (Quarter) stood at $122000.0 in 2018, then soared by 3865.57% to $4.8 million in 2020, then tumbled by 96.65% to $162000.0 in 2021, then changed by 0.0% to $162000.0 in 2022.
  • Its last three reported values are $162000.0 in Q2 2022, $162000.0 for Q1 2022, and $162000.0 during Q4 2021.